Burney Co. Boosts Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Burney Co. lifted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 297.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 507,044 shares of the biopharmaceutical company’s stock after purchasing an additional 379,501 shares during the period. Burney Co.’s holdings in Dynavax Technologies were worth $6,551,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in DVAX. Royce & Associates LP raised its holdings in Dynavax Technologies by 0.7% in the 2nd quarter. Royce & Associates LP now owns 442,257 shares of the biopharmaceutical company’s stock worth $5,714,000 after purchasing an additional 3,071 shares during the period. Stonepine Capital Management LLC purchased a new stake in Dynavax Technologies in the 1st quarter worth approximately $4,086,000. Credit Suisse AG raised its stake in Dynavax Technologies by 4.6% during the 1st quarter. Credit Suisse AG now owns 191,071 shares of the biopharmaceutical company’s stock worth $1,874,000 after acquiring an additional 8,366 shares during the period. Citigroup Inc. boosted its position in shares of Dynavax Technologies by 35.0% in the first quarter. Citigroup Inc. now owns 489,649 shares of the biopharmaceutical company’s stock worth $4,803,000 after purchasing an additional 126,979 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Dynavax Technologies in the first quarter worth $710,000. 99.13% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CMO Robert Janssen sold 5,015 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $15.03, for a total value of $75,375.45. Following the sale, the chief marketing officer now directly owns 49,925 shares in the company, valued at approximately $750,372.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CMO Robert Janssen sold 5,015 shares of Dynavax Technologies stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $15.03, for a total value of $75,375.45. Following the completion of the transaction, the chief marketing officer now owns 49,925 shares in the company, valued at approximately $750,372.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO David F. Novack sold 20,000 shares of the stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $15.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 3,187 shares in the company, valued at approximately $47,805. The disclosure for this sale can be found here. In the last ninety days, insiders sold 141,627 shares of company stock worth $2,092,122. 9.31% of the stock is currently owned by insiders.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $13.80 on Wednesday. The company has a current ratio of 15.40, a quick ratio of 14.49 and a debt-to-equity ratio of 0.37. Dynavax Technologies Co. has a 12 month low of $9.42 and a 12 month high of $15.15. The stock has a 50 day moving average of $14.06 and a 200 day moving average of $13.31. The firm has a market cap of $1.78 billion, a PE ratio of 35.39 and a beta of 1.44.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com initiated coverage on shares of Dynavax Technologies in a report on Thursday, October 5th. They issued a “hold” rating for the company. HC Wainwright lifted their target price on Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Finally, JMP Securities upped their price target on Dynavax Technologies from $25.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Friday, November 3rd.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.